Innovative Research in Cancer Nanotechnology (R01 Clinical Trial Not Allowed)

Innovative Research in Cancer Nanotechnology (R01 Clinical Trial Not Allowed)

Due Date: 05/04/2026

Supports transformative, mechanistic research using nanotechnology to overcome major barriers in cancer biology/oncology, emphasizing fundamental understanding of nano–bio interactions, in vivo delivery to cancer targets, and characterization of diagnostic/detection devices in vitro. Clinical translation and clinical trials are out of scope.

Eligibility criteria:

  • Eligible U.S. applicant types include: public/private higher education institutions, nonprofits (with/without 501(c)(3)), for-profits (incl. small businesses), state/local/tribal governments, independent school districts, special districts, public housing authorities, and faith-/community-based and regional organizations.

  • Foreign (non-U.S.) organizations are not eligible; non-domestic components of U.S. organizations are not eligible.

  • Foreign components (per NIH policy) are allowed.

  • Activity code: R01; clinical trials not allowed.

Funding details:

  • Award ceiling: USD 475,000.

Deadlines:

  • Current closing date for applications: May 04, 2026.

Where to go for further information: